双氢麦角胺甲磺酸盐结构式
|
常用名 | 双氢麦角胺甲磺酸盐 | 英文名 | Dihydro Ergotamine Mesylate |
|---|---|---|---|---|
| CAS号 | 6190-39-2 | 分子量 | 679.783 | |
| 密度 | N/A | 沸点 | 1001.8ºC at 760 mmHg | |
| 分子式 | C34H41N5O8S | 熔点 | 232°C | |
| MSDS | 中文版 美版 | 闪点 | 559.7ºC | |
| 符号 |
GHS07 |
信号词 | Warning |
双氢麦角胺甲磺酸盐用途Dihydroergotamine甲磺酸盐为麦角生物碱,可作用于偏头疼。 |
| 中文名 | 甲磺酸二氢麦角胺 |
|---|---|
| 英文名 | dihydroergotamine mesylate |
| 中文别名 | 双氢麦角胺甲磺酸盐 | 双氢麦角胺甲磺酸盐 | 甲磺双氢麦角胺 |
| 英文别名 | 更多 |
| 描述 | Dihydroergotamine甲磺酸盐为麦角生物碱,可作用于偏头疼。 |
|---|---|
| 相关类别 | |
| 参考文献 |
| 沸点 | 1001.8ºC at 760 mmHg |
|---|---|
| 熔点 | 232°C |
| 分子式 | C34H41N5O8S |
| 分子量 | 679.783 |
| 闪点 | 559.7ºC |
| 精确质量 | 679.267578 |
| PSA | 180.96000 |
| LogP | 2.87050 |
| 外观性状 | 白色粉末 |
| 折射率 | -20 ° (C=0.25, JP Method) |
| 储存条件 | Store at RT |
| 水溶解性 | methanol: 21 mg/mL |
| 分子结构 | 1、 摩尔折射率:164.20 2、 摩尔体积(m3/mol):416.5 3、 等张比容(90.2K):1236.7 4、 表面张力(dyne/cm):77.6 5、 极化率(10 -24cm 3):65.09 |
| 计算化学 | 1、 氢键供体数量:4 2、 氢键受体数量:9 3、 可旋转化学键数量:4 4、 互变异构体数量:2 5、 拓扑分子极性表面积(TPSA):173 6、 重原子数量:48 7、 表面电荷:0 8、 复杂度:1260 9、 同位素原子数量:0 10、 确定原子立构中心数量: 7 11、 不确定原子立构中心数量:0 12、 确定化学键立构中心数量:0 13、 不确定化学键立构中心数量:0 14、 共价键单元数量:2 |
| 更多 | 1. 性状:白色粉末。 2. 密度(g/mL, 25 ℃ ):未确定 3. 相对蒸汽密度(g/mL,空气=1):未确定 4. 熔点(ºC):232 5. 沸点(ºC,常压):未确定 6. 沸点(ºC,0.6mmHg):未确定 7. 折射率:未确定 8. 闪点(ºF):未确定 9. 比旋光度(º):未确定 10. 自燃点或引燃温度(ºC):未确定 11. 蒸气压(20ºC):未确定 12. 饱和蒸气压(kPa,60ºC):未确定 13. 燃烧热(KJ/mol):未确定 14. 临界温度(ºC):未确定 15. 临界压力(KPa):未确定 16. 油水(辛醇/水)分配系数的对数值:未确定 17. 爆炸上限(%,V/V):未确定 18. 爆炸下限(%,V/V):未确定 19. 溶解性:溶于甲醇,21mg/mL |
| 双氢麦角胺甲磺酸盐上游产品 0 | |
|---|---|
| 双氢麦角胺甲磺酸盐下游产品 1 | |
|
Role of 5-HT1B/1Dreceptors in the reduction of formalin-induced nociception and secondary allodynia/hyperalgesia produced by antimigraine drugs in rats
Life Sci. 92(22) , 1046-54, (2013) Aims The present study analyzed the potential antinociceptive effect of the antimigraine drugs sumatriptan, dihydroergotamine or methysergide in rats submitted to the formalin test. Moreover, by using... |
|
|
Structural basis for molecular recognition at serotonin receptors.
Science 340(6132) , 610-4, (2013) Serotonin or 5-hydroxytryptamine (5-HT) regulates a wide spectrum of human physiology through the 5-HT receptor family. We report the crystal structures of the human 5-HT1B G protein-coupled receptor ... |
|
|
Intrapulmonary and intravenous administrations of dihydroergotamine mesylate have similar cardiovascular effects in the conscious dog.
Br. J. Pharmacol. 154(6) , 1254-65, (2008) The effects of intrapulmonary artery (i.p.a.) administration of dihydroergotamine mesylate (DHE) were evaluated.Conscious beagle dogs (n=4) were given DHE via the i.p.a. or i.v. route as two 0.014 mg ... |
| Methansulfonsäure--(6aR,9R,10aR)-N-[(2R,5S,10aS,10bS)-5-benzyl-10b-hydroxy-2-methyl-3,6-dioxooctahydro-8H-[1,3]oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl]-7-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]chinolin-9-carboxamid(1:1) |
| Ikaran |
| EINECS 228-235-6 |
| dihydroergotamine methane sulfonate salt |
| Ergotaman, 9,10-dihydro-12'-hydroxy-2'-methyl-3',6',18-trioxo-5'-(phenylmethyl)-, (5'α,10α)-, methanesulfonate (1:1) (salt) |
| dihydroergotamine methanesulfonate |
| Dihydroergotamine mesylate,9,10-Dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotaman-3',6',18-trionemesylate |
| Methansulfonsäure--(6aR,9R,10aR)-N-[(2R,5S,10aS,10bS)-5-benzyl-10b-hydroxy-2-methyl-3,6-dioxooctahydro-8H-[1,3]oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl]-7-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4, |
| (6aR,9R,10aR)-N-[(2R,5S,10aS,10bS)-5-benzyl-10b-hydroxy-2-methyl-3,6-dioxooctahydro-8H-[1,3]oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl]-7-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-ca |
| dolo[4,3-fg]quinoléine-9-carboxamide (1:1) |
| Agit |
| Ergont |
| DET MS |
| MFCD00058615 |
| (5'α,10α)-5'-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman methanesulfonate (salt) |
| (5'α,10α)-5'-Benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman methanesulfonate (1:1) |
| (6aR,9R,10aR)-N-[(2R,5S,10aS,10bS)-5-benzyl-10b-hydroxy-2-methyl-3,6-dioxooctahydro-8H-[1,3]oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl]-7-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide methanesulfonate (salt) |
| dhe45 |
| rboxamide methanesulfonate (salt) |
| Diergo |
| acide méthanesulfonique - (6aR,9R,10aR)-N-[(2R,5S,10aS,10bS)-5-benzyl-10b-hydroxy-2-méthyl-3,6-dioxooctahydro-8H-[1,3]oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl]-7-méthyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoléine-9-carboxamide (1:1) |
| acide méthanesulfonique - (6aR,9R,10aR)-N-[(2R,5S,10aS,10bS)-5-benzyl-10b-hydroxy-2-méthyl-3,6-dioxooctahydro-8H-[1,3]oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl]-7-méthyl-4,6,6a,7,8,9,10,10a-octahydroin |
| Morena |
| Migranal |